Company: VCYT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001384101-25-000051
Chunk: 54

Company: VERACYTE, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 54
---
x Genomics (TXG)*                      |     | Adaptive Biotechnologies (ADPT) |     | Amicus Therapeutics (FOLD)* |
| CareDx (CDNA)                            |     | Cytek Biosciences (CTKB)        |     | Exact Sciences (EXAS)       |
| Fulgent Genetics (FLGT)*                 |     | Glaukos (GKOS)*                 |     | Guardant Health (GH)        |
| Invitae (NVTA)                           |     | Maravai Lifesciences (MRVI)*    |     | Myriad Genetics (MYGN)      |
| Natera (NTRA)                            |     | NeoGenomics (NEO)               |     | Nevro (NVRO)*               |
| Pacific Biosciences of California (PACB) |     | Twist Bioscience (TWST)         |     | Vericel (VCEL)              |

^ Castle Biosciences, Codexis and NanoString Technologies were removed from the peer list due to no longer fitting the criteria.

* New in 2024.

At the time of approval, Veracyte was near the 50th percentile for revenue and market capitalization, reinforcing the balance in the group of companies.

#### Veracyte2025 Proxy Statement51

#### Executive Compensation

#### Consideration of Compensation Risk
Our compensation governance practices provide an appropriate framework for our executives to achieve our strategic goals without encouraging them to take excessive risks in their business decisions.

On an annual basis, the Compensation Committee conducts a thorough risk assessment of our compensation programs and practices to analyze whether they encourage employees to take excessive or inappropriate risks. After conducting this analysis, the Compensation Committee concluded our compensation programs are, on balance, consistent with market practice and do not present material risks to us. The reasons for the Compensation Committee’s determination include the following:

• We structure our compensation programs to consist of both fixed and variable components. The fixed (or base salary) component of our compensation programs is designed to provide income independent of our stock price performance so that employees will not focus exclusively on stock price performance to the detriment of other important business metrics. The variable (cash bonus and equity) components of our compensation programs are designed to reward both short- and long-term company performance, which we believe discourages employees from taking actions that focus only on our short-term success and helps align our employees with our stockholders and on our longer-term success.

• We maintain internal controls over the measurement